Navigation Links
Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders
Date:4/21/2011

nterests when considering Valeant's non-binding proposal.REVOKE YOUR CONSENT ON THE WHITE CARD TODAY – DO NOT CONSENT TO VALEANT'S PROPOSALS!You can reject Valeant's efforts to take control of Cephalon by taking the following steps:1. Do not sign Valeant's gold consent card;

2. If you have signed Valeant's gold consent card, you may revoke that consent by signing, dating and mailing the enclosed WHITE Consent Revocation Card immediately; and

3. Even if you have not signed Valeant's gold consent card, you can show your support for your Board by signing, dating and mailing the enclosed WHITE Consent Revocation Card.

Regardless of the number of shares of Cephalon common stock that you own, it is important that you sign, date and mail the enclosed WHITE Consent Revocation Card to Cephalon TODAY. Thank you for your support.

Sincerely yours,

THE BOARD OF DIRECTORS OF CEPHALON, INC.

Your Consent Revocation Is Important, No Matter How Many Shares You Own.If you have questions about how to revoke your consent on the WHITE consent revocation card, or need additional assistance, please contact the firmassisting us in the solicitation of consent revocations:INNISFREE M&A INCORPORATEDTOLL-FREE: (877) 800-5186Banks and Brokers call collect: (212) 750-5833IMPORTANTWe urge you NOT to sign any gold consent card sent to you by ValeantAdditional Information:

Cephalon, Inc. (the "Company"), its directors and certain of its officers and employees may be deemed to be participants in the solicitation of consent revocations from stockholders in connection with a consent solicitation by Valeant Pharmaceuticals International, Inc. ("Valeant") to replace the Company's current Board of Directors with nominees of Valeant.

The Company has filed its definitive Consent Revocation Statement with the SEC and has mailed the definitive Consent Revocation Statement and WHITE consent revocation
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
6. Cephalon Reports Another Strong Quarter
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... Intrexon Corporation (NYSE: XON ), a ... its previously announced public offering of common stock, including ... option to purchase an additional 731,707 shares of common ... share.  The exercise of the underwriters, option brought the ... Intrexon to 5,609,756 shares and increased the total gross ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... CORAL SPRINGS, Florida , August 26, 2015 ... one of the biggest factors fueling the optimism ... FDA approvals, M&A,s, collaborations and life sciences advancements.  ... and developments are Pressure BioSciences, Inc. (OTCQB: PBIO), ... Inc. (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... to Hold Conference Call Today, March 13, 2008 at 11:00 ... DNDN ) today reported results for the year and ... 31, 2007 were,$743,000 compared to $273,000 for the year ended ... $28,000, compared to $86,000,for the same period in 2006., ...
... VANCOUVER and SAN DIEGO, March 13 /PRNewswire-FirstCall/ - MIGENIX ... for infectious,diseases, reports financial results for the three and ... its programs., Jim DeMesa, M.D., President & CEO ... quarter and now being halfway through our,fourth quarter, we ...
... Patented cathode materials result in longer-lasting, safer batteries for ... ... The U.S. Department of Energy,s,(DOE) Argonne National Laboratory and ... agreement for the commercial production and,sales of Argonne,s patented composite ...
Cached Biology Technology:Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 2Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 3Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 4Dendreon Reports Fourth Quarter and 2007 Year End Financial Results 5MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 2MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 3MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 4MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 5MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 6MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 7MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 8MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 9MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 10MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 11MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 12MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 13MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 14MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 15MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results 16Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... of the IOF Board and leading researcher at the ... of the prestigious Pierre Delmas Award. The award was ... Osteoarthritis (ESCEO13-IOF), currently being held in Rome, Italy. ... (IOF) in memory of Pierre D. Delmas, IOF,s renowned ...
... between road traffic and heart disease has been suggested in ... Denmark showed that traffic noise was significantly associated with risk ... noise exposure (either at the time of the attack or ... increased risk.(1) Now, a new study presented at the ...
... Albert Einstein College of Medicine of Yeshiva University ... in white blood cells is regulated. HIV-1 is the virus ... approaches for addressing HIV-1 "in hiding" namely eliminating reservoirs ... study was published today in the online edition of the ...
Cached Biology News:Pierre Delmas Award presented in Rome to Professor Socrates Papapoulos 2Long-term exposure to fine particles of traffic pollution increases risk of heart disease 2Discovery may help prevent HIV 'reservoirs' from forming 2
... Features, Special optically clear polystyrene formulation ... in immunoassay applications , Plates are ... coefficients of variation , Eight-well strips ... strip loss while in use even if ...
...
... Pierce scientists developed the Easy-Titer Human IgM ... a simple, sensitive, and easy-to-perform assay for ... an ELISA. This kit incorporates a simple ... of IgM concentration from 15-500 ng/ml in ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
Biology Products: